When It Comes To Biosimilar Marketing, Two Roads Diverge
Executive Summary
Amgen believes manufacturing nuances will set biosimilars apart and pave the way for Amgen to become a leader in the field. Others say it is a risky move to play up differences in the burgeoning market because of physician and patient concerns about the safety of biosimilars.
You may also be interested in...
Amgen's Amjevita Approved As First Biosimilar To AbbVie's Humira
Company starts 'a new chapter' with the first approval out of its biosimilar pipeline, which happens to be for the biggest drug in the world.
Amgen's Amjevita Approved As First Biosimilar To AbbVie's Humira
Company starts 'a new chapter' with the first approval out of its biosimilar pipeline, which happens to be for the biggest drug in the world.
Defender Or Opponent? Amgen Straddles The Biosimilar Line
Amgen revealed plans to develop and launch biosimilar versions of Abbott’s Humira and Johnson & Johnson’s Remicade – two competitors to its blockbuster anti-TNF Enbrel – during an investor meeting in New York City Feb. 7.